Pharmaceutical API Powder CAS 53123-88-9 Rapamycin

• Customization: Available
• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Appearance: White Powder
• Shelf Life: 2 Years
• Storage: Keep in Cool and Dry Place
• Delivery: Express 5-7 Days Arrive
• Test Method: HPLC
• Assay: 99%
• Shipping Area: Worldwide/All Countries
• CAS: 53123-88-9
• Service: Good Service
• Delivery Method: FedEx/DHL/Special Line
• Product Name: Rapamycin
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 200kg Per Month

Product Description

Pharmaceutical API Powder CAS 53123-88-9 Rapamycin

Specification of Analysis

Product Name	Rapamycin Powder
CAS	53123-88-9
Appearance	White crystalline powder
Molecular formula	C51H79NO13
Molecular Weight	914.18
Assay	98%
Shelf Life	24 months when properly stored

What is Rapamycin?

Rapamycin is a member of the macrolide immunosuppressant family and a FRAP inhibitor. 

Rapamycin exhibits binding and inhibitory actions to the FK506 binding protein (FKBP5) proline rotamase via simultaneous binding by FKBP12 and FRAP. FRAP (RAFT1) proteins exhibit homology to PI 4- and PI 3-kinases,which have PI 4-kinase and autophosphorylating activities.

The rapamycin/FKBP complex does not inhibit the FRAP PI 4-kinase activity,but does inhibit FRAP autophosphorylation. 

Rapamycin is unique in its ability to inhibit lymphokine induced cell proliferation at the G1 and S phase as well as an irreversible cellular arrest at the G1 phase in S. cerevisiae cells. 

Rapamycin also exhibits selective signal blocking leading to the activation of p70/85 S6 kinase, which is
potentially due to the inhibition of FRAP autophosphorylation or protein kinase activity. Angiogenesis inhibition is also exhibited,possibly through the inhibition of the Akt pathway. 

Rapamycin is an inhibitor of mTOR.
 

Function
 

Rapamycin is a triene macrolide antibiotic,which demonstrates anti-fungal,anti-inflammatory,anti-tumor and
immunosuppressive properties.

Rapamycin has been shown to block T-cell activation and proliferation,as well as,the activation of p70 S6 kinase and
exhibits strong binding to FK506 binding proteins. 

Rapamycin also inhibits the activity of the protein,mTOR(mammalian target of rapamycin) which functions in a
signaling pathway to promote tumor growth.

Rapamycin binds to a receptor protein (FKBP12) and the rapamycin/FKB12 complex then binds to mTOR and prevents
interaction of mTOR with target proteins in this signaling pathway.

 

Rapamycin (RAPA) is a novel macrolide immunosuppressant is now often used as a transplanted organ to maintain
immunity drugs (especially kidney transplants), to mitigate the immune organ rejection after transplant surgery, but
scientists it recently found another purpose: for the treatment of Alzheimer's disease (senile dementia).

Target of rapamycin (mTOR) as an intracellular kinases pathway abnormalities can induce a variety of diseases. As
rapamycin mTOR inhibitor targeting, to treat with this pathway is closely related to tumors, including renal cell
carcinoma, lymphoma, lung cancer, liver cancer, breast cancer, neuroendocrine carcinoma and gastric cancer